Product Description
Basic Info.
Mazdutide is a dual agonist of the GLP-1receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).
The drug is developed by Eli Lilly and is currently in multiple Phase III studies.
In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
Factory
Well-Equipped Filter Physical and Chemical Laboratory
To solidify product qualityfoundations and establishan industry-leading r&Dand testing system,the companyinvested in2014to
build a wel-equipped, fully-functional provincial-level filter physical and chemical laboratory. Designed and constructed in strict accor-
dance with the highest national and industry standards, the laboratory is outfitted with world-class precision testing instruments and
experimental equipment.
In 2016, leveraging its exceptional quality management capabilities and standardized production operations, the company successfully
achieved ISO/Ts 16949:2009 certification-the most authoritative quality management system recognized by the global automotive in-
dustry--becoming one of the select few enterprises in the sector to earn this distinguished honor.



















